image
Healthcare - Medical - Diagnostics & Research - NASDAQ - US
$ 54.965
-1.43 %
$ 10.4 B
Market Cap
-9.83
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Jun, 6, 2025.

The intrinsic value of one EXAS stock under the worst case scenario is HIDDEN Compared to the current market price of 55 USD, Exact Sciences Corporation is HIDDEN

This DCF valuation model was last updated on Jun, 6, 2025.

The intrinsic value of one EXAS stock under the base case scenario is HIDDEN Compared to the current market price of 55 USD, Exact Sciences Corporation is HIDDEN

This DCF valuation model was last updated on Jun, 6, 2025.

The intrinsic value of one EXAS stock under the best case scenario is HIDDEN Compared to the current market price of 55 USD, Exact Sciences Corporation is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart EXAS

image
$65.0$65.0$60.0$60.0$55.0$55.0$50.0$50.0$45.0$45.0$40.0$40.015 Dec15 DecJan '25Jan '2515 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '2515 Apr15 AprMay '25May '2515 May15 MayJun '25Jun '25
FINANCIALS
2.76 B REVENUE
10.37%
-1.05 B OPERATING INCOME
-387.74%
-1.03 B NET INCOME
-403.97%
211 M OPERATING CASH FLOW
34.86%
-442 M INVESTING CASH FLOW
-890.02%
232 M FINANCING CASH FLOW
45.13%
707 M REVENUE
-0.93%
-96 M OPERATING INCOME
89.04%
-101 M NET INCOME
0.00%
30.8 M OPERATING CASH FLOW
-34.54%
-34.4 M INVESTING CASH FLOW
17.76%
-256 M FINANCING CASH FLOW
-2439.96%
Balance Sheet Exact Sciences Corporation
image
Current Assets 1.57 B
Cash & Short-Term Investments 1.04 B
Receivables 249 M
Other Current Assets 284 M
Non-Current Assets 4.36 B
Long-Term Investments 0
PP&E 811 M
Other Non-Current Assets 3.55 B
17.51 %4.20 %4.80 %13.67 %59.82 %Total Assets$5.9b
Current Liabilities 732 M
Accounts Payable 89.6 M
Short-Term Debt 249 M
Other Current Liabilities 393 M
Non-Current Liabilities 2.79 B
Long-Term Debt 2.32 B
Other Non-Current Liabilities 473 M
7.07 %11.16 %65.83 %13.40 %Total Liabilities$3.5b
EFFICIENCY
Earnings Waterfall Exact Sciences Corporation
image
Revenue 2.76 B
Cost Of Revenue 840 M
Gross Profit 1.92 B
Operating Expenses 2.97 B
Operating Income -1.05 B
Other Expenses -19.8 M
Net Income -1.03 B
3b3b3b3b2b2b2b2b1b1b500m500m00(500m)(500m)(1b)(1b)(1b)(1b)3b(840m)2b(3b)(1b)20m(1b)RevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
69.55% GROSS MARGIN
69.55%
-38.01% OPERATING MARGIN
-38.01%
-37.29% NET MARGIN
-37.29%
-42.83% ROE
-42.83%
-17.36% ROA
-17.36%
-19.12% ROIC
-19.12%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Exact Sciences Corporation
image
100m100m00(100m)(100m)(200m)(200m)(300m)(300m)(400m)(400m)(500m)(500m)20162016201720172018201820192019202020202021202120222022202320232024202420252025
Net Income -1.03 B
Depreciation & Amortization 215 M
Capital Expenditures -136 M
Stock-Based Compensation 215 M
Change in Working Capital 0
Others 820 M
Free Cash Flow 74.5 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Exact Sciences Corporation
image
Wall Street analysts predict an average 1-year price target for EXAS of $75.3 , with forecasts ranging from a low of $60 to a high of $95 .
EXAS Lowest Price Target Wall Street Target
60 USD 9.16%
EXAS Average Price Target Wall Street Target
75.3 USD 37.01%
EXAS Highest Price Target Wall Street Target
95 USD 72.84%
Price
Max Price Target
Min Price Target
Average Price Target
100100909080807070606050504040Jul '24Jul '24Aug '24Aug '24Oct '24Oct '24Nov '24Nov '2420252025Feb '25Feb '25Apr '25Apr '25Jun '25Jun '25Jul '25Jul '25Aug '25Aug '25Oct '25Oct '25Nov '25Nov '2520262026Feb '26Feb '26Apr '26Apr '26Jun '26Jun '26
4. DIVIDEND ANALYSIS
5. COMPETITION
slide 2 of 11
6. Ownership
Insider Ownership Exact Sciences Corporation
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
130 K USD 1
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
1 M USD 1
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Should You Continue to Hold EXAS Sciences Stock in Your Portfolio? EXAS rides on strong Cologuard and Oncotype DX growth, but rising costs and high debt may test its staying power. zacks.com - 1 week ago
Exact Sciences Announces Expanded Clinical Validation of the Oncodetect™ Test and Molecular Residual Disease Innovation Roadmap MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today announced new data to be presented from the Beta-CORRECT clinical validation study at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. Results from Beta-CORRECT, a subset of the GALAXY cohort, validate the performance of its tumor-informed molecular residual disease (MRD) test, Oncodetect™, in predicting recurrence in stage II–IV colorectal. businesswire.com - 2 weeks ago
Exact Sciences to Participate in June Investor Conference MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that company management will participate in the following conference and invited investors to participate by webcast. William Blair 45th Annual Growth Stock Conference, Chicago Presentation on Tuesday, June 3, 2025 at 9:40 a.m. ET The webcast can be accessed in the investor relations section of Exact Sciences' website at www.exactsciences.com. About E. businesswire.com - 2 weeks ago
Exact Sciences Highlights Innovations in Early Cancer Detection and Precision Oncology at ASCO 2025 MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today announced it will present ten abstracts at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place May 30–June 3, 2025, in Chicago, Ill. Presentations include new data on the Oncodetect™ molecular residual disease (MRD) test, multi-cancer early detection (MCED) testing, the Oncotype DX Breast Recurrence Score® test, and the Cologuard®. businesswire.com - 3 weeks ago
2 Brilliant Stocks to Buy With $200 and Hold for 5 Years While being an innovative company doesn't guarantee superior long-term returns, it doesn't hurt those chances either. In fact, when a corporation is making important breakthroughs and boasts significant growth prospects in its industry, that could translate to above-average stock market performances over five years or more. fool.com - 1 month ago
Exact Sciences Earns 2025 Great Place To Work® Certification™ MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, announced today that it has been certified as a 2025 Great Place To Work® for the seventh consecutive year in the U.S., and for the first time in the U.K., Japan, Canada, France, Italy, Poland, and Germany. The recognition is based on a confidential survey of employees around the world, offering an independent assessment of Exact Sciences' culture, work environment, and le. businesswire.com - 1 month ago
Exact Sciences Q1 Earnings: Decent Quarter, But Growth Story Not Compelling Exact Sciences Corporation posted solid Q1 2025 earnings with revenues up 11% year-on-year, driven by strong performance in screening and Precision Oncology segments. Despite the sequential revenue decline, the market response was positive due to promising growth projections and the launch of Cologuard Plus, a next-gen colon cancer screening test. Competition and high market cap valuation pose challenges, but Exact's first-mover advantage and new product launches offer potential for continued revenue growth. seekingalpha.com - 1 month ago
Cancer Diagnostic Firm Exact Sciences' CEO Says Strong Q1 Paves Way For 'Transformative' 2025, Lifts Annual Guidance Exact Sciences Corp. EXAS on Thursday reported a first-quarter 2025 EPS loss of 21 cents, down from a 37-cent loss a year ago, beating the analyst consensus loss estimate of 38 cents. benzinga.com - 1 month ago
EXAS Stock Up on Q1 Earnings & Revenue Beat, 2025 Sales View Raised Exact Sciences ends the first quarter of 2025 on a solid note. zacks.com - 1 month ago
Exact Sciences to Participate in May Investor Conference MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that company management will participate in the following conference and invited investors to participate by webcast. BofA Securities Health Care Conference, Las Vegas Fireside chat on Wednesday, May 14, 2025 at 1:40 p.m. ET (10:40 a.m. PT) The webcast can be accessed in the investor relations section of Exact Sciences' website at www.exactsciences.co. businesswire.com - 1 month ago
Exact Sciences Corporation (EXAS) Q1 2025 Earnings Call Transcript Exact Sciences Corporation. (NASDAQ:EXAS ) Q1 2025 Earnings Conference Call May 1, 2025 5:00 PM ET Company Participants Derek Leckow - Vice President, Investor Relations Kevin Conroy - Chairman and Chief Executive Officer Aaron Bloomer - Chief Financial Officer Brian Baranick - General Manager, Precision Oncology Conference Call Participants Tycho Peterson - Jefferies Catherine Schulte - Baird Brandon Couillard - Wells Fargo Colleen Babington - Wolfe Research Patrick Donnelly - Citi Michael Ryskin - Bank of America Vijay Kumar - Evercore ISI Puneet Souda - Leerink Partners Subu Nambi - Guggenheim Andrew Brackmann - William Blair Luke Sergott - Barclays. seekingalpha.com - 1 month ago
Exact Sciences (EXAS) Reports Q1 Loss, Tops Revenue Estimates Exact Sciences (EXAS) came out with a quarterly loss of $0.21 per share versus the Zacks Consensus Estimate of a loss of $0.37. This compares to loss of $0.50 per share a year ago. zacks.com - 1 month ago
8. Profile Summary

Exact Sciences Corporation EXAS

image
COUNTRY US
INDUSTRY Medical - Diagnostics & Research
MARKET CAP $ 10.4 B
Dividend Yield 0.00%
Description Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX, a gene expression tests for breast, prostate, and colon cancers; Oncotype Test, a tissue test delivering tumor profiling to aid therapy selection for patients with advanced, metastatic, refractory, or recurrent cancer; Oncotype DX AR-V7 Nucleus Detect Test, a liquid-based test for advanced stage prostate cancer; Oncomap ExTra, that provides a complete biological picture of certain refractory, rare, or aggressive cancers; and Covid-19 testing services. The company's pipeline products focus on enhancing the Cologuard test's performance characteristics and developing blood and other fluid-based tests. It has license agreements with MAYO Foundation for Medical Education and Research; and Hologic, Inc. Exact Sciences Corporation was incorporated in 1995 and is headquartered in Madison, Wisconsin.
Contact 5505 Endeavor Lane, Madison, WI, 53719 https://www.exactsciences.com
IPO Date Feb. 1, 2001
Employees 6900
Officers Dr. Jorge A. Garces Ph.D. Chief Science Officer Mr. James Herriott Senior Vice President, General Counsel & Secretary Mr. Nassar Nizami Chief Information Officer Mr. Brian Baranick Executive Vice President & General Manager of Precision Oncology Mr. Graham P. Lidgard Ph.D. Emeritus Chief Science Officer Mr. Aaron Bloomer Chief Financial Officer Ms. Sarah Condella Executive Vice President of Human Resources Mr. Jacob Orville MBA Executive Vice President & GM of Screening Derek Leckow Vice President of Investor Relations Mr. Kevin T. Conroy J.D. Chairman of the Board & Chief Executive Officer